Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters
4 hours ago • Google News
Septerna, Inc. Common Stock (SEPN)
US$ 6.460%
Price Chart
Key Statistics
Market Cap
$ 0
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
173.34K
52W High
$ 28.99
52W Low
$ 4.17
Dividend Yield
0.00%
Beta
0.00
Technicals
50-Day MA
N/A
200-Day MA
N/A
52 Week High
28.99
52 Week Low
4.17
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflamm.
Employees
75
Headquarters
South San Francisco, CA
CEO
Dr. Jeffrey T. Finer M.D., Ph.D.
Latest News
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal (SEPN) - Bloomberg.com
5 hours ago • Google News
Septerna stock jumps on pact with Novo Nordisk (SEPN:NASDAQ) - Seeking Alpha
8 hours ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg